Health · Medical Research · 1 hr ago
Remplir shows early promise in five prostate cancer surgery cases
Orthocell says its Remplir product was used in robotic prostate cancer surgery for five men aged 57 to 69.
The men had advanced cancer, and surgery required extensive tissue removal, including nerves on the affected side.
Remplir is a collagen wrap designed to protect nerves and support healing after surgery.
Three men were able to urinate without pads within six months, while two had urinary symptoms before surgery and did not reach that point.
Of the four men who had erectile function before surgery, one reported function with oral medication at 12 months, two reported partial function with other treatment, and one had not regained function.
All five had undetectable PSA levels at the time of reporting, and no product-related complications were reported during surgery or about 12 months of follow-up.
The small case series offers early information, not proof that the product improves recovery.
Orthocell plans a larger prospective study, while the product is already being used in more than 300 prostatectomy procedures in Australia.
Orthocell reported early functional recovery outcomes from a five-patient case series of Remplir in men undergoing robotic prostate cancer surgery.
Three patients achieved pad-free urinary continence within six months of surgery.
Among four patients who had erectile function before surgery, one reported function with oral medication alone at 12 months.
All five patients had undetectable prostate-specific antigen levels at the time of reporting.
Orthocell plans a larger prospective study and said Remplir has been used in more than 300 Australian prostatectomy procedures.
- Who
- Orthocell and five men with advanced prostate cancer who underwent robotic surgery.
- What
- An initial case series reported early recovery outcomes and no Remplir-related complications. Orthocell plans a larger study.
- When
- The series followed patients for about 12 months; the article was published on 13 October 2026.
- Where
- The procedures were prostatectomies; the article does not state where the five operations took place.
- Why
- To assess Remplir’s feasibility and early outcomes in prostate cancer surgery and inform a larger prospective study.
This story does not have two clearly opposing sides.
All five men had advanced prostate cancer, and the extent of their disease required extensive tissue removal.
Three of the five patients achieved pad-free urinary continence.
One of the four patients who had erectile function before surgery reported function with oral medication alone.
All five patients had undetectable prostate-specific antigen levels.
- Patients
- 5 men aged 57–69
- Continence
- 3 patients achieved pad-free continence within 6 months
- Erectile function
- 1 of 4 patients with pre-surgery function reported function with oral medication alone at 12 months
- PSA
- All 5 patients had undetectable levels at reporting
- Australian use
- More than 300 prostatectomy procedures
- Remplir approvals
- 7 jurisdictions, including Australia, New Zealand and the US
Sources
Related news
Pope Leo to have surgery to remove an early-detected lung nodule
Pope Leo XIV to have surgery to remove early-stage lung nodule
Infections linked to 12% of cancer cases worldwide in 2024
Favorite music linked to lower pain during needle procedures
Pope Leo XIV to have lung nodule removed in surgery this week
‘Double diabetes’ combines type 1 diabetes with insulin resistance
Study finds existing food preferences can hinder learning new food values
Deworming Drug Slows Growth of Drug-Resistant Lung Cancer in Mice
Woman gives birth after ovarian tissue frozen for more than 20 years
Higher Weight at Dementia Diagnosis Linked to Lower Risk of Death
